Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ABSK021 versus placebo in tenosynovial giant cell tumor
2023-503245-58-00Phase 3Authorised
- Sponsor
- Abbisko Therapeutics
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial in tenosynovial giant cell tumor (TGCT) comparing ABSK021 with Placebo (2 arms). Primary endpoint: 25-Week Objective Response Rate by RECIST 1.1. Planned start Oct 2023; status: authorised.
02
Drugs
pimicotinib
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on 2023-503245-58-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503245-58-00.